Integer Holdings Co. (NYSE:ITGR) Short Interest Down 6.6% in January

Integer Holdings Co. (NYSE:ITGR) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 2,130,000 shares, a drop of 6.6% from the January 15th total of 2,280,000 shares. Based on an average daily volume of 212,300 shares, the short-interest ratio is currently 10.0 days. Approximately 6.6% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Loomis Sayles & Co. L P increased its stake in shares of Integer by 3.0% in the third quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock valued at $69,943,000 after purchasing an additional 15,446 shares during the period. Jane Street Group LLC increased its position in Integer by 23.3% in the 3rd quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock valued at $19,682,000 after acquiring an additional 28,572 shares during the period. Verition Fund Management LLC raised its stake in Integer by 17.4% during the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical equipment provider’s stock valued at $451,000 after acquiring an additional 515 shares in the last quarter. Versant Capital Management Inc boosted its position in Integer by 98.4% during the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 183 shares during the period. Finally, Lord Abbett & CO. LLC grew its stake in shares of Integer by 3.5% in the third quarter. Lord Abbett & CO. LLC now owns 290,120 shares of the medical equipment provider’s stock worth $37,716,000 after purchasing an additional 9,754 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Stock Up 0.1 %

Shares of Integer stock traded up $0.18 during trading on Tuesday, reaching $141.18. The company had a trading volume of 42,454 shares, compared to its average volume of 207,906. The company has a market cap of $4.74 billion, a price-to-earnings ratio of 43.64, a price-to-earnings-growth ratio of 1.79 and a beta of 1.13. Integer has a fifty-two week low of $97.49 and a fifty-two week high of $146.36. The firm’s fifty day moving average is $137.90 and its 200-day moving average is $132.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.09 and a current ratio of 3.28.

Analyst Ratings Changes

Several research firms have weighed in on ITGR. Benchmark raised their target price on shares of Integer from $130.00 to $140.00 and gave the company a “buy” rating in a report on Monday, October 21st. Truist Financial upped their price objective on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Citigroup lifted their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. KeyCorp raised their target price on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $140.00 price objective (up from $125.00) on shares of Integer in a research report on Friday, October 25th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $146.56.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.